CoChat
Sign Up
Cited by 61

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Hepcidin: A novel peptide hormone regulating iron metabolism

Singh, Bhawna, Arora, Sarika, Agrawal, Poonam, Gupta, S.K.·2011·Clinica Chimica Acta
DOI 10.1016/j.cca.2011.02.014
Open this paper in CoChat — free account

Abstract

Background Hepcidin is a low-molecular weight hepatic peptide regulating iron homeostasis. Hepcidin inhibits the cellular efflux of iron by binding to, and inducing the internalization and degradation of, ferroportin, the exclusive iron exporter in iron-transporting cells. It has been recently recognized as a main hormone behind anemia of chronic disease. Method A comprehensive literature search was conducted from the websites of Pubmed Central, the US National Library of Medicine's digital archive of life sciences literature (http://www.pubmedcentral.nih.gov/) and the National Library of Medicine (http://www.ncbl.nlm.nih.gov). The data was also assessed from journals and books that published relevant articles in this field. Result Hepcidin regulates iron uptake constantly on a daily basis, to maintain sufficient iron stores for erythropoiesis. Hepcidin, by its iron regulatory action on iron metabolism may be expected to have an important role in immune regulation, inflammatory diseases and malignancies. Hepcidin is the underlying cause of anemia in these clinical settings. Conclusion Hepcidin analysis may prove to be a novel tool for differential diagnosis and monitoring of disorders of iron metabolism, and establishment of therapeutic measures in various disease conditions like hereditary hemochromatosis, anemia associated with chronic kidney disease, rheumatoid arthritis and cancers.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.cca.2011.02.014

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 29 references

Research works printed but not linked: 77

  1. Aisen, 2001, Chemistry and biology of eukaryotic iron metabolism, Int J Biochem Cell Biol, 33, 940, 10.1016/S1357-2725(01)00063-2 · DOI · Paper page
  2. Nicolas, 2001, Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice, Proc Natl Acad Sci U S A, 98, 8780, 10.1073/pnas.151179498 · DOI · Paper page
  3. Ganz, 2004, Hepcidin in iron metabolism, Curr Opin Hematol, 11, 251, 10.1097/00062752-200407000-00004 · DOI
  4. Nemeth, 2003, Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein, Blood, 101, 2461, 10.1182/blood-2002-10-3235 · DOI · Paper page
  5. Hunter, 2002, The solution structure of human hepcidin, a peptide hormone with antimicrobial activity that is involved in iron uptake and hereditary hemochromatosis, J Biol Chem, 277, 37597, 10.1074/jbc.M205305200 · DOI · Paper page
  6. Kemna, 2007, Mass spectrometry-based hepcidin measurements in serum and urine: analytical aspects and clinical implications, Clin Chem, 53, 620, 10.1373/clinchem.2006.079186 · DOI
  7. Risso, 2000, Leukocyte antimicrobial peptides: multifunctional effector molecules of innate immunity, J Leukoc Biol, 68, 785, 10.1189/jlb.68.6.785 · DOI
  8. Nicolas, 2002, Severe iron deficiency anemia in transgenic mice expressing liver hepcidin, PNAS, 99, 4596, 10.1073/pnas.072632499 · DOI · Paper page
  9. Fleming, 1998, Mammalian iron transport: an unexpected link between metal homeostasis and host defense, J Lab Clin Med, 132, 464, 10.1016/S0022-2143(98)90123-8 · DOI
  10. Andrews, 2002, Metal transporters and disease, Curr Opin Chem Biol, 6, 181, 10.1016/S1367-5931(02)00307-1 · DOI
  11. Andrews, 1999, Disorders of iron metabolism, N Engl J Med, 341, 1986, 10.1056/NEJM199912233412607 · DOI · Paper page
  12. Ganz, 2006, Hepcidin and its role in regulating systemic iron metabolism, Hematol Am Soc Hematol Educ Program, 507, 29, 10.1182/asheducation-2006.1.29 · DOI
  13. Fleming, 2001, Hepcidin: a putative iron regulatory hormone relative to hereditary hemochromatosis and the anemia of chronic disease, Proc Natl Acad Sci U S A, 98, 8160, 10.1073/pnas.161296298 · DOI · Paper page
  14. Finch, 1994, Regulators of iron balance in humans, Blood, 84, 1697, 10.1182/blood.V84.6.1697.1697 · DOI · Paper page
  15. Nemeth, 2004, Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization, Science, 306, 2090, 10.1126/science.1104742 · DOI · Paper page
  16. Njajou, 2002, Dominant hemochromatosis due to N144H mutation of SLC11A3: clinical and biological characteristics, Blood Cells Mol Dis, 29, 439, 10.1006/bcmd.2002.0581 · DOI
  17. Peyssonnaux, 2006, TLR4-dependent hepcidin expression by myeloid cells in response to bacterial pathogens, Blood, 107, 3727, 10.1182/blood-2005-06-2259 · DOI · Paper page
  18. Dallalio, 2006, Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations, Blood, 107, 2702, 10.1182/blood-2005-07-2854 · DOI
  19. Gangaidzo, 2001, Association of pulmonary tuberculosis with increased dietary iron, J Infect Dis, 184, 936, 10.1086/323203 · DOI · Paper page
  20. Braun, 1999, Bacterial solutions to the iron-supply problem, Trends Biochem Sci, 24, 104, 10.1016/S0968-0004(99)01359-6 · DOI
  21. Jurado, 1997, Iron, infections, and anemia of inflammation, Clin Infect Dis, 25, 888, 10.1086/515549 · DOI · Paper page
  22. Walker, 2000, Effects of iron overload on the immune system, Ann Clin Lab Sci, 30, 354
  23. Weiss, 2002, Iron and immunity: a double-edged sword, Eur J Clin Investig, 32, 70, 10.1046/j.1365-2362.2002.0320s1070.x · DOI · Paper page
  24. Bogdan, 2001, Nitric oxide and the regulation of gene expression, Trends Cell Biol, 11, 66, 10.1016/S0962-8924(00)01900-0 · DOI
  25. Recalcati, 1998, Response of monocyte iron regulatory protein activity to inflammation: abnormal behavior in genetic hemochromatosis, Blood, 91, 2565, 10.1182/blood.V91.7.2565 · DOI
  26. Weiss, 1992, Iron modulates interferon-gamma effects in the human myelomonocytic cell line THP-1, Exp Hematol, 20, 605
  27. Weinberg, 2000, Modulation of intramacrophage iron metabolism during microbial cell invasion, Microbes Infect, 2, 85, 10.1016/S1286-4579(00)00281-1 · DOI
  28. Dey, 1994, Leishmanial glycosomes contain superoxide dismutase, Biochem J, 301, 317, 10.1042/bj3010317 · DOI
  29. Zhang, 1991, Genetic analysis of superoxide dismutase, the 23kilodalton antigen of mycobacterium tuberculosis, Mol Microbiol, 5, 381, 10.1111/j.1365-2958.1991.tb02120.x · DOI
  30. Nicolas, 2002, Hepcidin, a new iron regulatory peptide, Blood Cells Mol Dis, 29, 327, 10.1006/bcmd.2002.0573 · DOI
  31. Kemna, 2008, Hepcidin: from discovery to differential diagnosis, Haematologica, 93, 90, 10.3324/haematol.11705 · DOI
  32. Shike, 2002, Bass hepcidin is a novel antimicrobial peptide induced by bacterial challenge, Eur J Biochem, 269, 2232, 10.1046/j.1432-1033.2002.02881.x · DOI
  33. Tussing-Humphreys, 2010, Elevated systemic hepcidin and iron depletion in obese premenopausal females, Obesity, 18, 1449, 10.1038/oby.2009.319 · DOI
  34. Ganz, 2008, Immunoassay for human serum hepcidin, Blood, 112, 4292, 10.1182/blood-2008-02-139915 · DOI · Paper page
  35. Locke, 1932, The copper and non-hemoglobinous iron contents of the blood serum in disease, J Clin Invest, 11, 527, 10.1172/JCI100432 · DOI
  36. Weinstein, 2002, Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease, Blood, 100, 3776, 10.1182/blood-2002-04-1260 · DOI · Paper page
  37. Weiss, 2002, Pathogenesis and treatment of anaemia of chronic disease, Blood Rev, 16, 87, 10.1054/blre.2002.0193 · DOI
  38. Means, 2003, Recent developments in the anemia of chronic disease, Curr Hematol Rep, 2, 116
  39. Laftah, 2004, Effect of hepcidin on intestinal iron absorption in mice, Blood, 103, 3940, 10.1182/blood-2003-03-0953 · DOI · Paper page
  40. Cartwright, 1966, The anemia of chronic disorders, Semin Hematol, 3, 351
  41. Means, 1992, Progress in understanding the pathogenesis of the anemia of chronic disease, Blood, 80, 1639, 10.1182/blood.V80.7.1639.1639 · DOI
  42. Kuiper-Kramer, 1996, Analytical and clinical implications of soluble transferrin receptor in serum, Eur J Clin Chem Clin Biochem, 34, 645
  43. Rivera, 2008, The role of hepcidin in anemia of inflammation and anemia of cancer, FASEB, 22, 1191.8, 10.1096/fasebj.22.1_supplement.1191.8 · DOI
  44. Andrews, 2004, Anemia of inflammation: the cytokine–hepcidin link, J Clin Invest, 113, 1251, 10.1172/JCI21441 · DOI
  45. Cavill, 2002, Iron and erythropoietin in renal disease, Nephrol Dial Transplant, 17, 19, 10.1093/ndt/17.suppl_5.19 · DOI
  46. Sharma, 2008, Involvement of hepcidin in the anemia of multiple myeloma, Clin Cancer Res, 14, 3262, 10.1158/1078-0432.CCR-07-4153 · DOI
  47. Chung, 2006, Giant hepatocellular adenoma presenting with chronic iron deficiency anemia, Am J Gastroenterol, 101, 2160, 10.1111/j.1572-0241.2006.00607.x · DOI
  48. Simon, 1977, Idiopathic hemochromatosis: demonstration of recessive transmission and early detection by family HLA typing, N Engl J Med, 297, 1017, 10.1056/NEJM197711102971901 · DOI
  49. Lyon, 2001, Hereditary hemochromatosis since discovery of the HFE gene, Clin Chem, 47, 1147, 10.1093/clinchem/47.7.1147 · DOI
  50. Bridle, 2003, Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homeostasis, Lancet, 361, 669, 10.1016/S0140-6736(03)12602-5 · DOI · Paper page
  51. Swinkels, 2006, Hereditary hemochromatosis: genetic complexity and new diagnostic approaches, Clin Chem, 52, 950, 10.1373/clinchem.2006.068684 · DOI
  52. Papanikolaou, 2005, Hepcidin in iron overload disorders, Blood, 105, 4103, 10.1182/blood-2004-12-4844 · DOI · Paper page
  53. Nemeth, 2005, Hepcidin is decreased in TFR2-hemochromatosis, Blood, 105, 1803, 10.1182/blood-2004-08-3042 · DOI
  54. Cunningham, 2004, Complications of beta-thalassemia major in North America, Blood, 104, 34, 10.1182/blood-2003-09-3167 · DOI
  55. Jayantha, 2009, Hepcidin and inflammatory bowel disease: dual role in host defence and iron homoeostasis, Eur J Gastroenterol Hepatol, 21, 425, 10.1097/MEG.0b013e32830e2885 · DOI
  56. McGrath, 2004, Hepcidin: inflammation's iron curtain, Rheumatology, 43, 1323, 10.1093/rheumatology/keh345 · DOI
  57. Sabine, 2007, Inflammatory bowel disease, Gut, 56, 1240
  58. Bergamaschi, 2010, Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-treatment, Haematologica, 95, 199, 10.3324/haematol.2009.009985 · DOI
  59. Kemna, 2007, Regulation of hepcidin: insights from biochemical analysis on human serum samples, Blood Cells Mol Dis, 40, 339, 10.1016/j.bcmd.2007.10.002 · DOI
  60. Roe, 2007, Serum prohepcidin concentration: no association with iron absorption in healthy men, and no relationship with iron status in men carrying HFE mutations, hereditary haemochromatosis patients undergoing phlebotomy treatment, or pregnant woman, Br J Nutr, 97, 544, 10.1017/S0007114507336829 · DOI
  61. Barany, 1997, High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients, Am J Kidney Dis, 29, 565, 10.1016/S0272-6386(97)90339-5 · DOI
  62. Cooper, 2003, Increased expression of erythropoiesis inhibiting cytokines (IFN-gamma, TNF-alpha, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy, J Am Soc Nephrol, 14, 1776, 10.1097/01.ASN.0000071514.36428.61 · DOI
  63. Eschbach, 2002, Anemia management in chronic kidney disease: role of factors affecting epoetin responsiveness, J Am Soc Nephrol, 13, 1412, 10.1097/01.ASN.0000016440.52271.F7 · DOI
  64. Swinkels, 2008, Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease?, Nephrol Dial Transplant, 23, 2450, 10.1093/ndt/gfn267 · DOI
  65. Taes, 2004, Prohepcidin accumulates in renal insufficiency, Clin Chem Lab Med, 42, 387, 10.1515/CCLM.2004.069 · DOI
  66. Malyszko, 2006, Hepcidin, iron status, and renal function in chronic renal failure, kidney transplantation and hemodialysis, Am J Hematol, 81, 832, 10.1002/ajh.20657 · DOI
  67. Tomosugi, 2006, Detection of serum hepcidin in renal failure and inflammation by using Protein Chip system, Blood, 108, 1381, 10.1182/blood-2005-10-4043 · DOI
  68. Dayer, 2010, Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor, Rheumatology, 49, 15, 10.1093/rheumatology/kep329 · DOI
  69. Sullivan, 1989, The iron paradigm of ischemic heart disease, Am Heart J, 117, 1177, 10.1016/0002-8703(89)90887-9 · DOI
  70. Sullivan, 2005, Stored iron and vascular reactivity, Arterioscler Thromb Vasc Biol, 25, 1532, 10.1161/01.ATV.0000174124.20147.22 · DOI · Paper page
  71. Kraml, 2005, Iron loading increases cholesterol accumulation and macrophage scavenger receptor I expression in THP-1 mononuclear phagocytes, Metabolism, 54, 453, 10.1016/j.metabol.2004.10.012 · DOI
  72. Lee, 1999, Iron-deficient diet reduces atherosclerotic lesions in apoE-deficient mice, Circulation, 99, 1222, 10.1161/01.CIR.99.9.1222 · DOI · Paper page
  73. Kulaksiz, 2005, The iron-regulatory peptide hormone hepcidin: expression and cellular localization in the mammalian kidney, J Endocrinol, 184, 361, 10.1677/joe.1.05729 · DOI · Paper page
  74. Kemna, 2005, Novel urine hepcidin assay by mass spectrometry, Blood, 106, 3268, 10.1182/blood-2005-05-1873 · DOI
  75. Murphy, 2007, Quantitation of hepcidin from human and mouse serum using liquid chromatography tandem mass spectrometry, Blood, 110, 1048, 10.1182/blood-2006-11-057471 · DOI
  76. Murao, 2007, Simple and sensitive quantification of bioactive peptides in biological matrices using liquid chromatography/selected reaction monitoring mass spectrometry coupled with trichloroacetic acid clean-up, Rapid Commun Mass Spectrom, 21, 4033, 10.1002/rcm.3319 · DOI
  77. Young, 2009, Hepcidin for clinicians, Clin J Am Soc Nephrol, 4, 1384, 10.2215/CJN.02190309 · DOI

Cited by

Sorted by citations

Metadata

Authors
Singh, B., Arora, S., Agrawal, P., & Gupta, S. K.
Venue
Clinica Chimica Acta
Publisher
Elsevier BV
Published
2011-05
Volume
412
Issue
11-12
Pages
823-830
ISSN
0009-8981
DOI
10.1016/j.cca.2011.02.014
Cited by
61
References
29
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review